NHS primary care funding mandate for tirzepatide begins in England

Integrated Care Boards (ICBs) across England became legally required on June 23, 2025, to fund tirzepatide, sold as Mounjaro, for weight management in primary care settings for prioritized patient groups ^[1]. The requirement takes effect 180 days after NICE published its technology appraisal, TA1026, and applies alongside a separate 90-day mandate that already covers specialist weight management services ^[1].

NICE's appraisal recommends tirzepatide for adults with a body mass index (BMI) of at least 35 kg/m2 who also have at least one weight-related health condition, used together with a reduced-calorie diet and more physical activity ^[1]. For people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds, the BMI threshold is usually lowered by 2.5 kg/m2 ^[1].

The full population eligible under NICE's criteria is estimated at 3.4 million people ^[1]. Because funding that whole group immediately was not feasible, NHS England asked NICE for more time, and NICE's Guidance Executive approved a phased rollout instead of the standard 90-day timeline for primary care ^[1]. Under this plan, called the "cohorting approach," NHS England expects to reach roughly 220,000 patients through primary care over the first three years, from 2025 to 2028, with the remaining eligible population gaining access over as long as 12 years based on clinical need ^[1].

NHS England says obesity affects 29% of English adults, measured by a BMI of 30 or higher, and that 64% of adults live with overweight or obesity ^[1]. The agency estimates obesity costs the NHS about £11.4 billion a year, with broader societal costs, including lost productivity and social care, reaching an estimated £74.3 billion annually ^[1]. NHS England developed the prioritization approach after consulting ICBs, patients, healthcare professionals, charities, and Royal Colleges, citing its legal duty under Section 13Q of the National Health Service Act to involve the public in commissioning decisions ^[1].

Why it matters for patients

For patients in England, this means access to tirzepatide through a family doctor is now a funding requirement for some ICBs, but not an open offer to everyone who meets the BMI and comorbidity criteria ^[1]. NHS England describes the initial primary care phase as reflecting "available capacity," meaning only prioritized cohorts get access first, while the agency works out how to safely scale up delivery models ^[1]. Patients who meet NICE's eligibility criteria but fall outside the initial priority groups may need to wait, potentially for years, since NHS England's document notes the full eligible population could take up to 12 years to gain access ^[1].

NHS England also flags that tirzepatide carries Black Triangle status in the UK, a designation meaning the medicine is under additional monitoring, and that real-world use needs to be checked against the results seen in clinical trials ^[1]. The agency frames pharmacotherapy as one part of a larger obesity strategy that also includes lifestyle support, very low-calorie diets, and bariatric surgery, rather than a stand-alone solution ^[1].

What happens next

The specialist weight management service mandate has applied since March 24, 2025, covering the full eligible population in that setting ^[1]. The primary care mandate begins June 23, 2025, for prioritized cohorts only ^[1]. NHS England's guidance document was dated April 2, 2026, with amendments marked for that review, and the agency says it will continue evaluating implementation models in primary care during this initial phase before deciding how to expand access further ^[1]. Specific dates for when broader patient cohorts beyond the initial priority groups will gain primary care access are not detailed in the available guidance.